P53 Cancer Research Results

P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
581- Api,  Cisplatin,    The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
- in-vitro, Pca, CD44+
Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
2013- CAP,    Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, P53↑, P21↑, BAX↑, PSA↓, AR↓, NF-kB↓, Proteasome↓, TumVol↓, eff∅,
137- CUR,    Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
- in-vitro, Pca, DU145
NOTCH1↓, cycD1/CCND1↓, CDK2↓, P21↑, p27↑, P53↑, Bcl-2↓, Casp3↑, Casp9↑, TumCCA↑, TumCP↓, Apoptosis↑,
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
24- EGCG,  GEN,  QC,    Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin
- in-vitro, Pca, 22Rv1
NQO1↑, P53↑, NQO2↑, chemoPv↑, TumCP↓, AR↓,
4945- PEITC,    Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells
- in-vitro, Pca, DU145
AntiCan↑, TumCG↓, Apoptosis↑, tumCV↓, TumCCA↑, DNAdam↑, P53↑, CDC25↓, Casp9↑, Casp8↑, mtDam↑, Cyt‑c↑,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP↑,
100- QC,    Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓, TumCCA↑, chemoPv↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   GSH↑, 1,   HO-1↓, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 6,   ROS⇅, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   BCR↓, 1,   CDC16↓, 1,   CDC25↓, 1,   EGF↓, 2,   FGFR1↓, 1,   MMP↓, 3,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   cMyc↓, 3,   LDH↑, 1,   PI3K/Akt↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 5,   Bak↑, 1,   BAX↑, 7,   Bcl-2↓, 8,   Bcl-xL↓, 2,   BID↑, 1,   BIM↑, 2,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp8↑, 3,   Casp9↑, 5,   CBP↑, 1,   Cyt‑c↑, 4,   DR5↑, 2,   FasL↑, 1,   JNK↑, 1,   MAPK↓, 2,   MAPK↑, 1,   Mcl-1↓, 1,   MDM2↓, 2,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   NOXA↑, 1,   p27↑, 1,   p38↑, 2,   Proteasome↓, 1,   PUMA↑, 2,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

CDC7↓, 1,   HER2/EBBR2↓, 3,   RTK-RAS↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

miR-21↓, 1,   miR-21↑, 1,   p‑pRB↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 1,   GRP78/BiP↑, 2,   HSP70/HSPA5↓, 1,   NQO2↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B↑, 1,   LC3B-II↑, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   CUL4B↑, 1,   DNAdam↑, 2,   P53↑, 12,   p‑P53↑, 3,   PARP↓, 1,   PARP↑, 2,   p‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 3,   CDK2↓, 3,   CDK2↑, 1,   Cyc↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   cycF↓, 1,   E2Fs↓, 1,   P21↑, 7,   RB1↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

cDC2↓, 1,   CSCs↓, 1,   EMT↓, 2,   EP300↑, 1,   ERK↓, 1,   ERK↑, 1,   p‑ERK↑, 1,   FGF↓, 1,   IGFBP3↑, 1,   mTOR↓, 2,   NF2↑, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   PTEN↑, 1,   RAS↓, 1,   Shh↓, 2,   TumCG↓, 2,   TumCG↑, 1,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

CDK4/6↓, 2,   FAK↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 2,   MSH2↑, 1,   PDGF↓, 2,   RIP3↑, 1,   p‑RIP3↑, 1,   Sharpin↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TSC1↑, 1,   TSP-1↑, 1,   TumCP↓, 4,   uPA↓, 1,   uPAR↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   ATF4↑, 1,   EGFR↓, 3,   VEGF↓, 2,   VEGFR2↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 5,   p65↓, 1,   PSA↓, 2,   TLR4↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   Dose∅, 1,   eff↓, 2,   eff↑, 2,   eff∅, 1,   RadioS↑, 1,   selectivity↓, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 2,   BRCA1↑, 1,   CRP↓, 1,   EGFR↓, 3,   HER2/EBBR2↓, 3,   IL6↓, 1,   LDH↑, 1,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoPv↑, 2,   TGFβR1↑, 1,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 173

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
4 Apigenin (mainly Parsley)
4 Quercetin
3 Curcumin
2 Cisplatin
1 Metformin
1 Berberine
1 Radiotherapy/Radiation
1 Capsaicin
1 Docetaxel
1 EGCG (Epigallocatechin Gallate)
1 Genistein (soy isoflavone)
1 Phenethyl isothiocyanate
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page